FDA Grants Expedited Approval to Daraxonrasib for Pancreatic Cancer.

The FDA has granted expedited approval to daraxonrasib, a first-of-a-kind pill that targets a mutated protein present in over 90% of pancreatic cancers. The approval is US-wide. However, the expedited status means its real-world effectiveness and broad patient access are not yet demonstrated.

CHECKED · 1 SOURCE · UNCORROBORATED ✓